The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Travel, Accommodations, Expenses - Roche
Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Hanmi; Lilly; medpacto; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Novartis; Roche/Genentech
Other Relationship - Roche
 
Carlos H. Barrios
Stock and Other Ownership Interests - Biomarker; MedSIR; Tummi
Honoraria - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Eisai; GlaxoSmithKline; Libbs; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - AB Science; Abbvie; Abraxis BioScience; Amgen; Asana Biosciences; Astellas Pharma; AstraZeneca; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Celgene; Clinica Atlantis; Covance; Daiichi Sankyo; Daiichi Sankyo; Exelixis; GlaxoSmithKline; GlaxoSmithKline; Halozyme; ImClone Systems; INC Research; inVentiv Health; Janssen; LEO Pharma; Lilly; Medivation; Merck; Merrimack; Millennium; Mylan; Novartis; Pfizer; Roche/Genentech; Sanofi; Taiho Pharmaceutical
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Herve R. Bonnefoi
Honoraria - Roche
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Julie Gralow
Consulting or Advisory Role - AstraZeneca; Genentech; Genomic Health; Immunomedics; Merck; Novartis; Pfizer; Puma Biotechnology; Sandoz
 
Masakazu Toi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Genomic Health; Konica Minolta; Kyowa Hakko Kirin; Lilly; Novartis; Pfizer; Shimadzu; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Konica Minolta; Kyowa Hakko Kirin
Speakers' Bureau - AstraZeneca; Lilly; Pfizer
Research Funding - AFI technology; Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Japan Breast Cancer Research Group; Kyoto Breast cancer Research Network; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Shimadzu; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Travel, Accommodations, Expenses - Eisai; Takeda
Other Relationship - Japan Breast Cancer Research Group; Japan Breast Cancer Research Group; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research
 
Paul Ellis
No Relationships to Disclose
 
Luca Gianni
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Celgene; Daiichi Sankyo; Forty Seven; G1 Therapeutics; Genenta Science; Genentech; Genomic Health; Lilly; Merck Sharp & Dohme; METIS Precision Medicine; Novartis; Odonate Therapeutics; Oncolytics; Onkaido Therapeutics; Pfizer; Revolution Medicines; Roche; Sandoz; Seagen; Synaffix; Synthon; Taiho Pharmaceutical; Zymeworks
Research Funding - Celgene (Inst); Revolution Medicines (Inst); Zymeworks (Inst)
Patents, Royalties, Other Intellectual Property - Roche
Travel, Accommodations, Expenses - Celgene; Chugai Pharma; Pfizer; Roche
 
Sandra M. Swain
Consulting or Advisory Role - Athenex; Daiichi Sankyo; Daiichi Sankyo; Genentech/Roche; Genomic Health; Inivata; Lilly; Molecular Templates; Pieris Pharmaceuticals; Silverback Therapeutics; Tocagen
Research Funding - Genentech (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Caris Centers of Excellence; Caris Life Sciences; Daiichi Sankyo; Genentech/Roche; Inivata; Lilly; NanoString Technologies; Novartis
Other Relationship - AstraZeneca; Roche
 
Young-Hyuck Im
No Relationships to Disclose
 
Michelino De Laurentiis
Consulting or Advisory Role - Amgen; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Speakers' Bureau - Amgen; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Research Funding - Daiichi Sankyo; Macrogenics; Merck; Novartis; Roche
 
Zbigniew Nowecki
No Relationships to Disclose
 
Jigna Shah
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Thomas Boulet
Employment - Roche/Genentech
 
Haiying Liu
Employment - Genentech
Stock and Other Ownership Interests - Roche/Genentech
Travel, Accommodations, Expenses - Genentech/Roche
 
Harrison Macharia
Employment - Roche/Genentech
 
Peter Trask
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech; Pfizer
 
Chunyan Song
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Eric P. Winer
Stock and Other Ownership Interests - Verastem
Honoraria - Genentech/Roche; Genomic Health
Consulting or Advisory Role - Carrick Therapeutics; G1 Therapeutics; Genomic Health; GlaxoSmithKline; Jounce Therapeutics; Leap Therapeutics; Lilly; Seagen
Research Funding - Genentech (Inst); Novartis (Inst)
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Honoraria - AstraZeneca; Celltrion; Genentech/Roche
Consulting or Advisory Role - Context Therapeutics; Daiichi Sankyo; Genentech/Roche; ION Pharma; Macrogenics; Merck; Novartis; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)